DLBCL patients in these areas are more likely to suffer from HBV infection and harbour a higher mutation burden, including in CD70, and they may benefit from therapies that restore CD70/CD27 signalling. The gene discussed is CD70; the disease is diffuse large B-cell lymphoma.